During #SITC24 Moffitt’s Roger Li, MD (@UrogerliMD) discusses the combination of oncolytic virotherapy and nivolumab (C N) as a therapy for cisplatin-ineligible muscle-invasive bladder cancer (MIBC). #MoffittSITC24 @sitcancer  ➡️ Combination neoadjuvant treatment using Creto Nivo was well-tolerated and achieved pCR of 42.1%, compares favorably to SOC cisplatin-based chemotherapy ➡️ pCR associated with free E2F activity and tumor mutational burden ➡️ Treatment induced neoantigen specific systemic T-cell activation in responders ➡️ Formation and maturation of TLS specifically associated with complete response ➡️ Potential to enhance therapeutic efficacy in cisplatin-ineligible patients with MIBC ➡️ Cretostimogene may be an important contributor to checkpoint inhibitors in MIBC and HR NMIBC with future trials exploring monotherapy and rational combination strategies

Had a blast representing the Mid Atlantic section the at #AUA23 resident bowl: learned some new urology trivia, made friends with residents from other programs, and we defended the title for the second year in a row! 🥇🏆 💯 @AhmadAlZubeidi @AmrElbakryUro @ClintYeaman